AR066584A1 - Formulaciones farmaceuticas que contienen nicotina. uso. - Google Patents
Formulaciones farmaceuticas que contienen nicotina. uso.Info
- Publication number
- AR066584A1 AR066584A1 ARP080102064A ARP080102064A AR066584A1 AR 066584 A1 AR066584 A1 AR 066584A1 AR P080102064 A ARP080102064 A AR P080102064A AR P080102064 A ARP080102064 A AR P080102064A AR 066584 A1 AR066584 A1 AR 066584A1
- Authority
- AR
- Argentina
- Prior art keywords
- nicotine
- oral
- oral formulation
- amino acid
- tablet
- Prior art date
Links
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 title abstract 15
- 229960002715 nicotine Drugs 0.000 title abstract 13
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 title abstract 13
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 239000000203 mixture Substances 0.000 abstract 9
- 238000009472 formulation Methods 0.000 abstract 8
- 229940024606 amino acid Drugs 0.000 abstract 5
- 235000001014 amino acid Nutrition 0.000 abstract 5
- 150000001413 amino acids Chemical class 0.000 abstract 3
- 238000000034 method Methods 0.000 abstract 3
- 239000003826 tablet Substances 0.000 abstract 3
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 abstract 2
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 abstract 2
- 241000208125 Nicotiana Species 0.000 abstract 2
- 235000002637 Nicotiana tabacum Nutrition 0.000 abstract 2
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 abstract 2
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 abstract 2
- 208000025569 Tobacco Use disease Diseases 0.000 abstract 2
- 235000009508 confectionery Nutrition 0.000 abstract 2
- XVOYSCVBGLVSOL-UHFFFAOYSA-N cysteic acid Chemical compound OC(=O)C(N)CS(O)(=O)=O XVOYSCVBGLVSOL-UHFFFAOYSA-N 0.000 abstract 2
- YMAWOPBAYDPSLA-UHFFFAOYSA-N glycylglycine Chemical compound [NH3+]CC(=O)NCC([O-])=O YMAWOPBAYDPSLA-UHFFFAOYSA-N 0.000 abstract 2
- 238000004519 manufacturing process Methods 0.000 abstract 2
- 210000000214 mouth Anatomy 0.000 abstract 2
- 229960003104 ornithine Drugs 0.000 abstract 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 abstract 1
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 239000004475 Arginine Substances 0.000 abstract 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 abstract 1
- 206010009900 Colitis ulcerative Diseases 0.000 abstract 1
- 208000011231 Crohn disease Diseases 0.000 abstract 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 abstract 1
- 239000004471 Glycine Substances 0.000 abstract 1
- 108010008488 Glycylglycine Proteins 0.000 abstract 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 abstract 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 abstract 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 abstract 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 abstract 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 abstract 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 abstract 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 abstract 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 abstract 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 abstract 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 abstract 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 abstract 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 abstract 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 abstract 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 abstract 1
- 239000004472 Lysine Substances 0.000 abstract 1
- 206010057852 Nicotine dependence Diseases 0.000 abstract 1
- 208000018737 Parkinson disease Diseases 0.000 abstract 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 abstract 1
- 229920002472 Starch Polymers 0.000 abstract 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 abstract 1
- 239000004473 Threonine Substances 0.000 abstract 1
- 201000006704 Ulcerative Colitis Diseases 0.000 abstract 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 abstract 1
- -1 amino acid amino acid Chemical class 0.000 abstract 1
- 229960003121 arginine Drugs 0.000 abstract 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 abstract 1
- 235000009697 arginine Nutrition 0.000 abstract 1
- 229960001230 asparagine Drugs 0.000 abstract 1
- 235000009582 asparagine Nutrition 0.000 abstract 1
- 239000002775 capsule Substances 0.000 abstract 1
- 125000002091 cationic group Chemical group 0.000 abstract 1
- 229920002678 cellulose Polymers 0.000 abstract 1
- 239000001913 cellulose Substances 0.000 abstract 1
- 229940068682 chewable tablet Drugs 0.000 abstract 1
- 239000007910 chewable tablet Substances 0.000 abstract 1
- 229940112822 chewing gum Drugs 0.000 abstract 1
- 235000015218 chewing gum Nutrition 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000012458 free base Substances 0.000 abstract 1
- 229960002989 glutamic acid Drugs 0.000 abstract 1
- 235000013922 glutamic acid Nutrition 0.000 abstract 1
- 239000004220 glutamic acid Substances 0.000 abstract 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 abstract 1
- 229960002743 glutamine Drugs 0.000 abstract 1
- 235000004554 glutamine Nutrition 0.000 abstract 1
- 229960002449 glycine Drugs 0.000 abstract 1
- 229960002885 histidine Drugs 0.000 abstract 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 abstract 1
- 229960000310 isoleucine Drugs 0.000 abstract 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 abstract 1
- 229960003136 leucine Drugs 0.000 abstract 1
- 229960003646 lysine Drugs 0.000 abstract 1
- 229930182817 methionine Natural products 0.000 abstract 1
- 229960004452 methionine Drugs 0.000 abstract 1
- 239000004005 microsphere Substances 0.000 abstract 1
- 239000008203 oral pharmaceutical composition Substances 0.000 abstract 1
- 229960005190 phenylalanine Drugs 0.000 abstract 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 abstract 1
- 229960001153 serine Drugs 0.000 abstract 1
- 230000005586 smoking cessation Effects 0.000 abstract 1
- 230000000391 smoking effect Effects 0.000 abstract 1
- 239000008107 starch Substances 0.000 abstract 1
- 235000019698 starch Nutrition 0.000 abstract 1
- 229960002898 threonine Drugs 0.000 abstract 1
- 229960004295 valine Drugs 0.000 abstract 1
- 239000004474 valine Substances 0.000 abstract 1
- 238000004260 weight control Methods 0.000 abstract 1
- 239000010457 zeolite Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23G—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
- A23G3/00—Sweetmeats; Confectionery; Marzipan; Coated or filled products
- A23G3/34—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof
- A23G3/36—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds
- A23G3/44—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds containing peptides or proteins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23G—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
- A23G4/00—Chewing gum
- A23G4/06—Chewing gum characterised by the composition containing organic or inorganic compounds
- A23G4/14—Chewing gum characterised by the composition containing organic or inorganic compounds containing peptides or proteins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/175—Amino acids
-
- A—HUMAN NECESSITIES
- A24—TOBACCO; CIGARS; CIGARETTES; SIMULATED SMOKING DEVICES; SMOKERS' REQUISITES
- A24B—MANUFACTURE OR PREPARATION OF TOBACCO FOR SMOKING OR CHEWING; TOBACCO; SNUFF
- A24B15/00—Chemical features or treatment of tobacco; Tobacco substitutes, e.g. in liquid form
- A24B15/10—Chemical features of tobacco products or tobacco substitutes
- A24B15/16—Chemical features of tobacco products or tobacco substitutes of tobacco substitutes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/465—Nicotine; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
- A61K9/0058—Chewing gums
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nutrition Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Physiology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Inorganic Chemistry (AREA)
- Zoology (AREA)
- Psychiatry (AREA)
- Mycology (AREA)
- Addiction (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Una formulacion farmacéutica oral para proveer nicotina en cualquier forma a un sujeto por captacion transmucosa en la cavidad oral que comprende nicotina en cualquier forma, en donde dicha formulacion oral tiene un buffer de al menos un aminoácido,de preferencia al menos un aminoácido endogeno. También se contempla un método para la provision oral de nicotina en cualquier forma, un método para la reduccion de la urgencia de fumar o el uso de tabaco así como métodos para fabricar laformulacion oral, el uso de dicha formulacion oral para obtener captacion transmucosa de nicotina en la cavidad oral de un sujeto, y el uso de nicotina para la produccion de una formulacion oral para el tratamiento de una enfermedad seleccionado delgrupo que consiste en dependencia de tabaco o nicotina, enfermedad de Alzheimer, enfermedad de Crohn enfermedad de Parkinson, síndrome de Tourette, colitis ulcerosa y control de peso posterior al cese del hábito de fumar. Reivindicacion 3: Laformulacion oral de acuerdo con la reivindicacion 2, caracterizada porque el al menos un aminoácido en1ogeno se elige de arginina, asparagina, ácido glutámico, glutamina, glicina, histidina, isoleucina, leucina, lisina, metionina, ornitina,fenilalanina, serina, treonina y valina. Reivindicacion 5: La formulacion oral de acuerdo con la reivindicacion 1, caracterizada porque el al menos un aminoácido se elige de ácido cisteico, N-glicilglicina y ornitina. Reivindicacion 9: Laformulacion oral de acuerdo con cualquiera de las reivindicaciones 1-8, en donde la nicotina en cualquier forma se selecciona del grupo que consiste en una sal de nicotina, la forma de base libre de nicotina, un derivado de nicotina, tal como unintercambiador cationico de nicotina, un complejo de inclusion de nicotina o nicotina en cualquier union no covalente; nicotina unido a zeolitas; nicotina unido a celulosa o microesferas de almidon; y sus mezclas. Reivindicacion 17: La formulacionoral de acuerdo con cualquiera de las reivindicaciones 1-16 en la forma de rocío bucal, cápsula, goma de mascar, comprimido masticable, comprimido, comprimido fundido, pastilla, caramelo duro fundido, caramelo masticable, goma, o película oral.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE0701178 | 2007-05-16 | ||
US11/803,747 US20080286340A1 (en) | 2007-05-16 | 2007-05-16 | Buffered nicotine containing products |
Publications (1)
Publication Number | Publication Date |
---|---|
AR066584A1 true AR066584A1 (es) | 2009-09-02 |
Family
ID=40002443
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP080102064A AR066584A1 (es) | 2007-05-16 | 2008-05-15 | Formulaciones farmaceuticas que contienen nicotina. uso. |
Country Status (14)
Country | Link |
---|---|
US (1) | US20080286340A1 (es) |
EP (1) | EP2152313B1 (es) |
JP (1) | JP2010526875A (es) |
KR (1) | KR20100017820A (es) |
CN (1) | CN101795710A (es) |
AR (1) | AR066584A1 (es) |
AU (1) | AU2008251095B2 (es) |
BR (1) | BRPI0811110A2 (es) |
CA (1) | CA2685452A1 (es) |
MX (1) | MX2009012485A (es) |
NZ (1) | NZ580732A (es) |
RU (1) | RU2465904C2 (es) |
WO (1) | WO2008140371A1 (es) |
ZA (1) | ZA200908960B (es) |
Families Citing this family (104)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3473251B1 (en) | 2002-12-20 | 2023-12-13 | NicoNovum AB | A nicotine-cellulose combination |
AU2004259006B2 (en) * | 2003-07-24 | 2010-10-07 | Glaxosmithkline Llc | Orally dissolving films |
US10244793B2 (en) | 2005-07-19 | 2019-04-02 | Juul Labs, Inc. | Devices for vaporization of a substance |
WO2007104573A2 (en) | 2006-03-16 | 2007-09-20 | Niconovum Ab | Improved snuff composition |
BRPI0816890A2 (pt) * | 2007-09-18 | 2015-03-24 | Niconovum Ab | Composição de goma de mascar, uso de uma combinação de nicotina-celulose, maltitol e uma base de goma, e, método para a preparação de uma composição de goma de mascar |
CA2704209C (en) | 2007-10-31 | 2017-02-28 | Mcneil-Ppc, Inc. | Orally disintegrative dosage form |
PT2230934E (pt) | 2007-12-14 | 2012-11-20 | Aerodesigns Inc | Distribuir produtos alimentares aerossolizáveis |
US8991402B2 (en) | 2007-12-18 | 2015-03-31 | Pax Labs, Inc. | Aerosol devices and methods for inhaling a substance and uses thereof |
AR071420A1 (es) | 2008-05-01 | 2010-06-16 | Smithkline Beecham Corp | Composicion de pastilla para chupar oral que comprende un principio activo de nicotina y procedimiento para fabricarla |
CA2736531C (en) * | 2008-09-17 | 2016-10-25 | Niconovum Ab | Process for preparing snuff composition |
CN102316850A (zh) * | 2009-02-11 | 2012-01-11 | 海格兰德公司 | 一种用于戒烟的口腔吸收尼古丁组合物 |
US20100226904A1 (en) * | 2009-03-05 | 2010-09-09 | Hero Nutritionals, LLC | Organic chewable supplement |
US9610224B2 (en) | 2009-09-24 | 2017-04-04 | Johnson & Johnson Consumer Inc. | Manufacture of tablet in a die utilizing powder blend containing water-containing material |
US8858210B2 (en) | 2009-09-24 | 2014-10-14 | Mcneil-Ppc, Inc. | Manufacture of variable density dosage forms utilizing radiofrequency energy |
US8313768B2 (en) * | 2009-09-24 | 2012-11-20 | Mcneil-Ppc, Inc. | Manufacture of tablet having immediate release region and sustained release region |
RU2587570C2 (ru) | 2010-04-14 | 2016-06-20 | Алтрия Клаинт Сервисиз Инк. | Отформованный бездымный табачный продукт |
JP2013525394A (ja) * | 2010-04-27 | 2013-06-20 | ノバルティス アーゲー | 経口投与剤形 |
US20110268809A1 (en) | 2010-04-28 | 2011-11-03 | Paul Andrew Brinkley | Nicotine-Containing Pharmaceutical Compositions |
US20110274628A1 (en) | 2010-05-07 | 2011-11-10 | Borschke August J | Nicotine-containing pharmaceutical compositions |
CN102917687A (zh) * | 2010-05-13 | 2013-02-06 | 阿斯利康(瑞典)有限公司 | 镇静催眠剂的可注射乳液 |
US9474303B2 (en) | 2011-09-22 | 2016-10-25 | R.J. Reynolds Tobacco Company | Translucent smokeless tobacco product |
US20130078307A1 (en) | 2011-09-22 | 2013-03-28 | Niconovum Usa, Inc. | Nicotine-containing pharmaceutical composition |
US9084439B2 (en) | 2011-09-22 | 2015-07-21 | R.J. Reynolds Tobacco Company | Translucent smokeless tobacco product |
US9629392B2 (en) | 2011-09-22 | 2017-04-25 | R.J. Reynolds Tobacco Company | Translucent smokeless tobacco product |
US9907748B2 (en) | 2011-10-21 | 2018-03-06 | Niconovum Usa, Inc. | Excipients for nicotine-containing therapeutic compositions |
CN102511921B (zh) * | 2011-12-30 | 2014-02-26 | 华宝食用香精香料(上海)有限公司 | 一种膜状口含烟的制备方法 |
US20130177646A1 (en) * | 2012-01-05 | 2013-07-11 | Mcneil Ab | Solid Nicotine-Comprising Dosage Form with Reduced Organoleptic Disturbance |
US9763928B2 (en) * | 2012-02-10 | 2017-09-19 | Niconovum Usa, Inc. | Multi-layer nicotine-containing pharmaceutical composition |
US10799451B2 (en) * | 2012-03-27 | 2020-10-13 | Nicoccino Ab | Nicotine formulation |
CN104411297B (zh) * | 2012-03-27 | 2017-10-24 | 尼科辛诺公司 | 尼古丁制剂 |
US9044035B2 (en) | 2012-04-17 | 2015-06-02 | R.J. Reynolds Tobacco Company | Remelted ingestible products |
US9511028B2 (en) | 2012-05-01 | 2016-12-06 | Johnson & Johnson Consumer Inc. | Orally disintegrating tablet |
US9445971B2 (en) | 2012-05-01 | 2016-09-20 | Johnson & Johnson Consumer Inc. | Method of manufacturing solid dosage form |
US9233491B2 (en) | 2012-05-01 | 2016-01-12 | Johnson & Johnson Consumer Inc. | Machine for production of solid dosage forms |
US10517530B2 (en) | 2012-08-28 | 2019-12-31 | Juul Labs, Inc. | Methods and devices for delivering and monitoring of tobacco, nicotine, or other substances |
CN103099308A (zh) * | 2012-11-13 | 2013-05-15 | 苏州谷力生物科技有限公司 | 一种改性糊精烟用保润剂的制备方法 |
CA2898729C (en) | 2012-11-14 | 2018-05-08 | Abon Pharmaceuticals, Llc | Oral transmucosal drug delivery system |
US10130120B2 (en) | 2013-03-15 | 2018-11-20 | Altria Client Services Llc | Use of pectin or other anionic polymers in the stabilization and controlled release of nicotine in oral sensorial tobacco products or nicotine containing non-tobacco oral sensorial products |
US10799548B2 (en) | 2013-03-15 | 2020-10-13 | Altria Client Services Llc | Modifying taste and sensory irritation of smokeless tobacco and non-tobacco products |
US10279934B2 (en) | 2013-03-15 | 2019-05-07 | Juul Labs, Inc. | Fillable vaporizer cartridge and method of filling |
FR3005262A1 (fr) * | 2013-05-02 | 2014-11-07 | Philippe Gorny | Nouvelles compositions pharmaceutiques ou dietetiques permettant de masquer totalement l'amertume des sels d'arginine donnes a haute dose, sous forme liquide ou semi-liquide. |
CN117137195A (zh) | 2013-05-06 | 2023-12-01 | 尤尔实验室有限公司 | 用于气溶胶装置的烟碱盐调配物及其方法 |
CN111642812A (zh) | 2013-06-14 | 2020-09-11 | 尤尔实验室有限公司 | 电子汽化设备中的具有单独的可汽化材料的多个加热元件 |
KR102665932B1 (ko) | 2013-12-05 | 2024-05-13 | 쥴 랩스, 인크. | 에어로졸 장치를 위한 니코틴 액제 및 그 방법 |
USD842536S1 (en) | 2016-07-28 | 2019-03-05 | Juul Labs, Inc. | Vaporizer cartridge |
US10076139B2 (en) | 2013-12-23 | 2018-09-18 | Juul Labs, Inc. | Vaporizer apparatus |
US20160366947A1 (en) | 2013-12-23 | 2016-12-22 | James Monsees | Vaporizer apparatus |
US10058129B2 (en) | 2013-12-23 | 2018-08-28 | Juul Labs, Inc. | Vaporization device systems and methods |
US10159282B2 (en) | 2013-12-23 | 2018-12-25 | Juul Labs, Inc. | Cartridge for use with a vaporizer device |
USD825102S1 (en) | 2016-07-28 | 2018-08-07 | Juul Labs, Inc. | Vaporizer device with cartridge |
CN115281387A (zh) | 2013-12-23 | 2022-11-04 | 尤尔实验室有限公司 | 蒸发装置系统和方法 |
KR20160107254A (ko) | 2014-01-10 | 2016-09-13 | 존슨 앤드 존슨 컨수머 인코포레이티드 | 고주파 및 손실 코팅된 입자를 사용하여 정제를 제조하는 방법 |
CN103734904B (zh) * | 2014-01-21 | 2016-01-20 | 江苏中烟工业有限责任公司 | 一种滋阴降火型烟草口腔喷剂及其制备方法 |
US9375033B2 (en) | 2014-02-14 | 2016-06-28 | R.J. Reynolds Tobacco Company | Tobacco-containing gel composition |
CN103815542B (zh) * | 2014-02-21 | 2016-09-21 | 湖北中烟工业有限责任公司 | 四层烟用水胶囊及其制备方法 |
CA2944471C (en) * | 2014-04-08 | 2020-03-31 | Sansa Corporation (Barbados) Inc. | Nicotine formulations and methods of making the same |
WO2015175979A1 (en) | 2014-05-16 | 2015-11-19 | Pax Labs, Inc. | Systems and methods for aerosolizing a smokeable material |
CN103948164B (zh) * | 2014-05-19 | 2016-08-24 | 川渝中烟工业有限责任公司 | 口含烟提取液及其制备方法和口含烟 |
CN104082851A (zh) * | 2014-07-08 | 2014-10-08 | 山东津美生物科技有限公司 | 烟草粘合剂及其制备方法与应用 |
CN104068465B (zh) * | 2014-07-08 | 2016-02-03 | 川渝中烟工业有限责任公司 | 浓香型口含烟的制备方法 |
WO2016063423A1 (ja) * | 2014-10-24 | 2016-04-28 | 日本たばこ産業株式会社 | 口腔用たばこ組成物及びその製造方法 |
CA2969728C (en) | 2014-12-05 | 2023-06-13 | Pax Labs, Inc. | Calibrated dose control |
GB201511284D0 (en) * | 2015-06-26 | 2015-08-12 | Univ Witwatersrand Jhb | An oral pharmaceutical dosage form for the delivery of a peptide and/or protein |
JP6324349B2 (ja) * | 2015-06-26 | 2018-05-16 | 長谷川香料株式会社 | 塩味増強剤 |
CN104970445B (zh) * | 2015-07-21 | 2017-11-07 | 中国烟草总公司广东省公司 | 一种缓释型气雾口香烟 |
GB201516729D0 (en) * | 2015-09-22 | 2015-11-04 | The Technology Partnership Plc | Liquid nicotine formulation |
CN105230940B (zh) * | 2015-10-20 | 2021-06-22 | 贵州中烟工业有限责任公司 | 一种功能性硬质糖果及其制备方法 |
US20170165252A1 (en) | 2015-12-10 | 2017-06-15 | Niconovum Usa Inc. | Protein-enriched therapeutic composition |
BR112018016402B1 (pt) | 2016-02-11 | 2023-12-19 | Juul Labs, Inc | Cartuchos de fixação segura para dispositivos vaporizadores |
UA125687C2 (uk) | 2016-02-11 | 2022-05-18 | Джуул Лебз, Інк. | Заповнювальний картридж випарного пристрою та способи його заповнення |
US10405582B2 (en) | 2016-03-10 | 2019-09-10 | Pax Labs, Inc. | Vaporization device with lip sensing |
WO2017182084A1 (en) | 2016-04-21 | 2017-10-26 | Fertin Pharma A/S | Nicotine delivery product, related uses and oral dosage forms, and methods of production |
USD849996S1 (en) | 2016-06-16 | 2019-05-28 | Pax Labs, Inc. | Vaporizer cartridge |
USD836541S1 (en) | 2016-06-23 | 2018-12-25 | Pax Labs, Inc. | Charging device |
USD851830S1 (en) | 2016-06-23 | 2019-06-18 | Pax Labs, Inc. | Combined vaporizer tamp and pick tool |
USD848057S1 (en) | 2016-06-23 | 2019-05-07 | Pax Labs, Inc. | Lid for a vaporizer |
US20190133940A1 (en) * | 2016-06-30 | 2019-05-09 | Philip Morris Products S.A. | Nicotine particles and compositions |
US11660403B2 (en) | 2016-09-22 | 2023-05-30 | Juul Labs, Inc. | Leak-resistant vaporizer device |
US20180103681A1 (en) * | 2016-10-18 | 2018-04-19 | Altria Client Services Llc | Methods and systems for increasing stability of the pre-vapor formulation of an e-vaping device |
US10493026B2 (en) | 2017-03-20 | 2019-12-03 | Johnson & Johnson Consumer Inc. | Process for making tablet using radiofrequency and lossy coated particles |
EP3599892B1 (en) * | 2017-03-20 | 2024-04-03 | Bayer Healthcare LLC | Chewable gel products for active pharmaceutical ingredients |
CA3062146A1 (en) | 2017-05-22 | 2018-11-29 | Johnson & Johnson Consumer Inc. | Lozenge dosage form |
WO2019005889A1 (en) * | 2017-06-26 | 2019-01-03 | Nude Nicotine, Inc. | NICOTINE SALTS AND METHODS FOR PREPARING AND USING SAME |
USD887632S1 (en) | 2017-09-14 | 2020-06-16 | Pax Labs, Inc. | Vaporizer cartridge |
GB2569940B (en) * | 2017-11-01 | 2022-10-19 | Nicoventures Trading Ltd | Aerosolisable formulation |
ES2890975T3 (es) | 2017-12-08 | 2022-01-25 | Fertin Pharma As | Comprimido de nicotina |
US20200397691A1 (en) * | 2017-12-08 | 2020-12-24 | Fertin Pharma A/S | Nicotine mouth spray |
CN111432840B (zh) * | 2017-12-08 | 2023-10-20 | 费尔廷制药公司 | 固体经口烟碱制剂 |
EP3758675A1 (de) * | 2018-03-01 | 2021-01-06 | LTS Lohmann Therapie-Systeme AG | Orale darreichungsform mit theobrominfreiem kakao |
US20210255202A1 (en) | 2018-06-13 | 2021-08-19 | Michael R. D'Andrea | Methods and dosing regimens for preventing or delaying onset of alzheimer's disease and other forms of dementia and mild congnitive impairment |
GB201817865D0 (en) * | 2018-11-01 | 2018-12-19 | Nicoventures Trading Ltd | Aerosolisable formulation |
SE544446C2 (en) * | 2019-02-01 | 2022-05-31 | Swedish Match North Europe Ab | AN ORAL NICOTINE PRODUCT COMPRISING A pH ADJUSTING AGENT |
CN110384700A (zh) * | 2019-09-03 | 2019-10-29 | 云南喜科科技有限公司 | 一种合成尼古丁的组合物 |
JP2023504756A (ja) | 2019-12-09 | 2023-02-06 | ニコベンチャーズ トレーディング リミテッド | カンナビノイドを含む口腔用製品 |
US11541004B2 (en) | 2020-06-10 | 2023-01-03 | Howard University | Method for treating or mitigating Parkinson's disease using nicotine inhaler or nicotine nasal spray |
US11911375B2 (en) * | 2020-11-16 | 2024-02-27 | Fertin Pharma A/S | Solid oral nicotine formulation |
CN112841709B (zh) * | 2021-01-20 | 2022-11-25 | 深圳市艾普生物科技有限公司 | 一种尼古丁盐的制备方法及应用 |
DE102021105268A1 (de) | 2021-03-04 | 2022-09-08 | Lts Lohmann Therapie-Systeme Ag. | Oraler Dünnfilm |
US20220312826A1 (en) * | 2021-04-06 | 2022-10-06 | Altria Client Services Llc | Liquid mixtures of triglyceride and liquid nicotine |
US20220354785A1 (en) * | 2021-04-22 | 2022-11-10 | Nicoventures Trading Limited | Oral lozenge products |
JP2024515358A (ja) * | 2021-04-22 | 2024-04-09 | ニコベンチャーズ トレーディング リミテッド | 口腔用組成物及び製造方法 |
CA3231103A1 (en) * | 2021-10-08 | 2023-04-13 | Venda Porter MALONEY | Oral compositions comprising arginine and gelling agent |
CN113880802A (zh) * | 2021-11-09 | 2022-01-04 | 深圳萨特瓦生物科技有限公司 | 酒石酸-尼古丁盐及其制备方法与应用、无水酒石酸晶体的制备方法 |
WO2024037043A1 (zh) * | 2023-04-28 | 2024-02-22 | 深圳华宝协同创新技术研究院有限公司 | 用于口腔粘膜的包含尼古丁的薄膜组合物 |
Family Cites Families (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3877468A (en) * | 1970-07-22 | 1975-04-15 | Leo Ab | Chewable tobacco substitute composition |
US3901248A (en) * | 1970-07-22 | 1975-08-26 | Leo Ab | Chewable smoking substitute composition |
US3845217A (en) * | 1972-11-16 | 1974-10-29 | Helsingborg L Ab | Buffered smoking substitute compositions |
JPS55122709A (en) * | 1979-03-13 | 1980-09-20 | Asama Kasei Kk | Stench remover from mouth |
GB8615676D0 (en) * | 1986-06-26 | 1986-07-30 | Stoppers Co Ltd | Nicotine containing lozenge |
US5009893A (en) * | 1989-07-17 | 1991-04-23 | Warner-Lambert Company | Breath-freshening edible compositions of methol and a carboxamide |
US5733572A (en) * | 1989-12-22 | 1998-03-31 | Imarx Pharmaceutical Corp. | Gas and gaseous precursor filled microspheres as topical and subcutaneous delivery vehicles |
US5165943A (en) * | 1991-06-21 | 1992-11-24 | Wm. Wrigley Jr. Company | Cooling agent/cyclodextrin complex for improved flavor release |
SE9303574D0 (sv) * | 1993-11-01 | 1993-11-01 | Kabi Pharmacia Ab | Composition for drug delivery and method the manufacturing thereof |
US5652216A (en) * | 1994-05-26 | 1997-07-29 | Novo Nordisk A/S | Pharmaceutical preparation |
US5578563A (en) * | 1994-08-12 | 1996-11-26 | The Procter & Gamble Company | Composition for reducing malodor impression on inanimate surfaces |
US5698181A (en) * | 1994-12-09 | 1997-12-16 | Warner-Lambert Company | Breath-freshening edible compositions comprising menthol and an N-substituted-P-menthane carboxamide and methods for preparing same |
US5810018A (en) * | 1994-12-29 | 1998-09-22 | Monte; Woodrow C. | Method, composition and apparatus for reducing the incidence of cigarette smoking |
NL1002833C2 (nl) * | 1996-04-10 | 1997-04-03 | Gerardus Joannes Emile Maria N | Werkwijze, voor duurzame ontwenning van/aan nicotine en andere verslavende producten door toediening van sex steroide voorlopers (precursors), alsmede het gebruik van die voorlopers als medicijn. |
EP0803243B1 (en) * | 1996-04-24 | 2003-03-19 | Pfizer Inc. | Cyclodextrins and phenolic compounds in dental products |
US5866179A (en) * | 1996-05-03 | 1999-02-02 | Avant-Garde Technologies & Products S.A. | Medicated chewing gum and a process for preparation thereof |
WO1997042941A2 (en) * | 1996-05-13 | 1997-11-20 | Novartis Consumer Health S.A. | Buccal delivery system |
US5780020A (en) * | 1996-10-28 | 1998-07-14 | The Proctor & Gamble Company | Methods and compositions for reducing body odor |
US5885599A (en) * | 1996-10-28 | 1999-03-23 | The Procter & Gamble Company | Methods and compositions for reducing body odors and excess moisture |
US5942214A (en) * | 1997-06-09 | 1999-08-24 | The Procter & Gamble Company | Methods for controlling environmental odors on the body using compositions comprising uncomplexed cyclodextrins and perfume |
US6627233B1 (en) * | 1997-09-18 | 2003-09-30 | Wm. Wrigley Jr. Company | Chewing gum containing physiological cooling agents |
US6197288B1 (en) * | 1997-10-16 | 2001-03-06 | Bush Boake Allen, Inc. | Malodor counteractant compositions and method for preparing and using same |
IL142981A0 (en) * | 1998-11-25 | 2002-04-21 | Procter & Gamble | Improved uncomplexed cyclodextrin compositions for odor control |
US6680289B1 (en) * | 1999-09-02 | 2004-01-20 | The Proctor & Gamble Company | Methods, compositions, and articles for odor control |
US6497859B1 (en) * | 2000-11-17 | 2002-12-24 | Noville Inc. | Cooling agents, pharmaceutical compositions having cooling agents and processes for making and using same |
SE0102197D0 (sv) * | 2001-06-20 | 2001-06-20 | Pharmacia Ab | New product and use and manufacture thereof |
DE60105820D1 (de) * | 2001-10-22 | 2004-10-28 | Pera Ivo E | Zusammensetzung zur Reduzierung oder Entwöhnung von Nikotinabhängigkeit |
US20040037879A1 (en) * | 2001-11-02 | 2004-02-26 | Adusumilli Prasad S. | Oral controlled release forms useful for reducing or preventing nicotine cravings |
SE0104388D0 (sv) * | 2001-12-27 | 2001-12-27 | Pharmacia Ab | New formulation and use and manufacture thereof |
US20040101543A1 (en) * | 2002-03-22 | 2004-05-27 | John Liu | Nicotine-containing oral dosage form |
US20040018157A1 (en) * | 2002-07-25 | 2004-01-29 | Masters James G. | Oral composition providing enhanced oral hygiene properties |
US20040180110A1 (en) * | 2003-03-14 | 2004-09-16 | Atul Mistry | Chewing gum and confectionery compositions containing an endothermic agent |
DK1663168T3 (da) * | 2003-09-08 | 2009-06-08 | Mcneil Ab | Nikotinformuleringer og anvendelse deraf |
-
2007
- 2007-05-16 US US11/803,747 patent/US20080286340A1/en not_active Abandoned
-
2008
- 2008-04-21 JP JP2010508331A patent/JP2010526875A/ja active Pending
- 2008-04-21 WO PCT/SE2008/000277 patent/WO2008140371A1/en active Application Filing
- 2008-04-21 RU RU2009146576/15A patent/RU2465904C2/ru not_active IP Right Cessation
- 2008-04-21 CA CA002685452A patent/CA2685452A1/en not_active Abandoned
- 2008-04-21 BR BRPI0811110-3A2A patent/BRPI0811110A2/pt not_active IP Right Cessation
- 2008-04-21 EP EP08741851.3A patent/EP2152313B1/en not_active Not-in-force
- 2008-04-21 MX MX2009012485A patent/MX2009012485A/es active IP Right Grant
- 2008-04-21 KR KR1020097026179A patent/KR20100017820A/ko not_active Application Discontinuation
- 2008-04-21 NZ NZ580732A patent/NZ580732A/en not_active IP Right Cessation
- 2008-04-21 CN CN200880015891A patent/CN101795710A/zh active Pending
- 2008-04-21 AU AU2008251095A patent/AU2008251095B2/en not_active Ceased
- 2008-05-15 AR ARP080102064A patent/AR066584A1/es not_active Application Discontinuation
-
2009
- 2009-12-15 ZA ZA2009/08960A patent/ZA200908960B/en unknown
Also Published As
Publication number | Publication date |
---|---|
CN101795710A (zh) | 2010-08-04 |
NZ580732A (en) | 2012-05-25 |
MX2009012485A (es) | 2009-12-02 |
EP2152313A4 (en) | 2013-08-07 |
US20080286340A1 (en) | 2008-11-20 |
RU2009146576A (ru) | 2011-06-27 |
CA2685452A1 (en) | 2008-11-20 |
KR20100017820A (ko) | 2010-02-16 |
EP2152313B1 (en) | 2014-09-03 |
RU2465904C2 (ru) | 2012-11-10 |
EP2152313A1 (en) | 2010-02-17 |
AU2008251095A1 (en) | 2008-11-20 |
ZA200908960B (en) | 2011-02-23 |
JP2010526875A (ja) | 2010-08-05 |
AU2008251095B2 (en) | 2013-01-31 |
WO2008140371A1 (en) | 2008-11-20 |
BRPI0811110A2 (pt) | 2014-12-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR066584A1 (es) | Formulaciones farmaceuticas que contienen nicotina. uso. | |
AR060932A1 (es) | Producto y su uso y elaboracion | |
CY1123334T1 (el) | Σκευασματα φιναστεριδης για αποδεσμευση φαρμακου στα μαλλια και στο τριχωτο της κεφαλης | |
AR095456A1 (es) | Composiciones de dos componentes que contienen complejos de halogenuro de cinc y aminoácido y cisteína | |
BRPI0516238A (pt) | composição farmacêutica contendo diclofenaco | |
AR059006A1 (es) | Composiciones de un anticonvulsivo y metodos para usarlas para revertir el aumento de peso | |
AR060931A1 (es) | Producto farmaceutico recubierto para la administracion intraoral de nicotina y su uso y elaboracion | |
PE20110543A1 (es) | Formulacion solida oral que comprende linaclotida, cation de calcio y leucina | |
RU2009146580A (ru) | Состав, содержащий никотин, с покрытием для перорального применения с буферными свойствами, приданными аминокислотой | |
MX336038B (es) | Composiciones farmaceuticas de liberacion controlada de tapentadol. | |
EA201100896A1 (ru) | Композиция, предназначенная для всасывания никотина из ротовой полости с целью прекратить курение | |
PE20140960A1 (es) | Formulaciones que comprenden un inhibidor de dpp4 | |
PH12015500301A1 (en) | A novel formulation of diclofenac | |
BR112014009146A2 (pt) | formulações de etanercepte estabilizadas com aminoácidos | |
BR112012018384A2 (pt) | composição farmacêutica sólida com intensificadores e métodos de preparação da mesma. | |
UA104869C2 (uk) | Фармацевтичні композиції, що містять ліганди рецептора дофаміну | |
EA200702522A1 (ru) | Система доставки лекарств в полость рта и способы ее применения | |
AR070025A1 (es) | Uso de derivados de 1-amino-alquilciclohexano para el tratamiento del tinnitus coclear y composicion farmaceutica | |
CL2011001178A1 (es) | Uso de (r)-7-cloro-niquinuclidin-3-1l)senzo[b]tiofen0-2-carboxamida o una sal de la misma o una composicion farmaceutica que la comprende para preparar un medicamento util para mejorar la cognicion en un paciente que sufre de alzheimer o esquizofrenia. | |
TNSN07337A1 (en) | Pharmaceutical composition comprising an indolylmaleimide derivative | |
EA201170512A1 (ru) | Композиция для перорального введения | |
AR077384A1 (es) | Una formulacion farmaceutica inyectable de melfalano. | |
EA201591188A1 (ru) | Доставка глатирамера ацетата через слизистую оболочку | |
ECSP10010576A (es) | Formulaciones orales e inyectables de compuestos de tetraciclina | |
HUP0204202A2 (hu) | Ibuprofent tartalmazó hatóanyag-preparátum, eljárás az előállítására és ezt tartalmazó gyógyszerkészítmények |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |